Display Settings:

Format
Items per page

Send to:

Choose Destination

Results: 1 to 20 of 32

1.

Carcinoma of pancreas

Pancreatic cancer shows among the highest mortality rates of any cancer, with a 5-year relative survival rate of less than 5%. By the time of initial diagnosis, metastatic disease is commonly present. Established risk factors include a family history of pancreatic cancer, a medical history of diabetes type 2, and cigarette smoking (summary by Amundadottir et al., 2009). Genetic Heterogeneity of Pancreatic Cancer Somatic mutations in pancreatic cancer occur in the KRAS (190070), CDKN2A (600160), MADH4 (600993), TP53 (191170), ARMET (601916), STK11 (602216), ACVR1B (601300), and RBBP8 (604124) genes. Susceptibility loci for pancreatic cancer include PNCA1 (606856), related to mutation in the PALLD gene on chromosome 4q32 (608092); PNCA2 (613347), related to mutation in the BRCA2 gene on chromosome 13q12 (600185); PNCA3 (613348), related to mutation in the PALB2 gene on chromosome 16p12 (610355); and PNCA4 (614320), related to mutation in the BRCA1 gene on chromosome 17q21 (113705). Occurrence of Pancreatic Cancer in Other Disorders Several familial cancer syndromes increase the risk of pancreatic cancer. The best characterized include hereditary nonpolyposis colon cancer syndrome (HNPCC; see 120435); hereditary breast-ovarian cancer syndrome due to mutations in BRCA2; Peutz-Jeghers syndrome (175200); the melanoma-pancreatic cancer syndrome (606719), caused by mutations in CDKN2A (600160); von Hippel-Lindau syndrome (193300), ataxia-telangiectasia (208900) (Swift et al., 1976), and juvenile polyposis syndrome (174900). Patients with hereditary pancreatitis (167800) resulting from gain-of-function mutations in the protease serine-1 gene (PRSS1; 276000) have a lifetime pancreatic cancer risk ratio of 57 and a cumulative incidence, to age 70 years, of 40% (Lowenfels et al., 1997). [from OMIM]

MedGen UID:
65917
Concept ID:
C0235974
Neoplastic Process
2.

Gefitinib

MedGen UID:
450008
Concept ID:
CN077533
Pharmacologic Substance
3.

Disease Response

The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression. [from NCI]

MedGen UID:
309976
Concept ID:
C1704632
Finding
4.

Epidermal growth factor

A protein made by many cells in the body and by some types of tumors. It causes cells to grow and differentiate (become more specialized). It is a type of growth factor and a type of cytokine. [from NCI]

MedGen UID:
66867
Concept ID:
C0242275
Pharmacologic Substance
5.

A 7

MedGen UID:
56568
Concept ID:
C0163299
Pharmacologic Substance
6.

Anorexia

A disorder characterized by a loss of appetite. [from NCI]

MedGen UID:
315
Concept ID:
C0003123
Sign or Symptom
7.

Adenocarcinoma

A malignant neoplasm arising from glandular cells. [from NCI]

MedGen UID:
122
Concept ID:
C0001418
Neoplastic Process
8.

Vomiting

MedGen UID:
776588
Concept ID:
C2712332
Finding
9.

Error occurred: cannot get document summary

ID:
775793

10.

3/4

MedGen UID:
617755
Concept ID:
C0442757
Finding
11.

Detected

MedGen UID:
617726
Concept ID:
C0442726
Finding
12.

Pancreatic adenocarcinoma

The presence of an adenocarcinoma of the pancreas. [from HPO]

MedGen UID:
505959
Concept ID:
CN005854
Finding
13.

Neoplasm of the pancreas

A tumor (abnormal growth of tissue) of the pancreas. [from HPO]

MedGen UID:
425115
Concept ID:
CN002617
Finding
14.

Nausea

MedGen UID:
368427
Concept ID:
C1963179
Finding
15.

Diarrhea

MedGen UID:
368098
Concept ID:
C1963091
Finding
16.

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Substances that inhibit Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase, involved with signal transduction pathways, and may be useful in treating tumors that over express EGFR. [from NCI]

MedGen UID:
303178
Concept ID:
C1443775
Pharmacologic Substance
17.

Protein-tyrosine kinase inhibitor

Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals including cell proliferation. Inhibition of tyrosine kinase may result in inhibition of cell growth and cell proliferation. [from NCI]

MedGen UID:
266120
Concept ID:
C1268567
Pharmacologic Substance
18.

Pancreatic adenocarcinoma

An adenocarcinoma which arises from the exocrine pancreas. Ductal adenocarcinoma and its variants are the most common types of pancreatic adenocarcinoma. [from NCI]

MedGen UID:
83800
Concept ID:
C0281361
Neoplastic Process
19.

Epithelial Neoplasm

neoplasm of epithelial origin, ranging from benign (adenoma and papilloma) to malignant (carcinoma). [from CRISP]

MedGen UID:
277963
Concept ID:
C1368683
Neoplastic Process
20.

Praxel

MedGen UID:
276699
Concept ID:
C1518839
Pharmacologic Substance

Display Settings:

Format
Items per page

Send to:

Choose Destination

Supplemental Content

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...